University of Chicago Medical Center Radiation Oncology
Research Interests
Dr. Solanki's research focuses on advancing the treatment of patients with genitourinary cancers, brain and spine tumors, metastases from cancer, and optimizing quality and safety in radiation oncology. These interests include the treatment of prostate cancer with high-dose-rate (HDR) prostate brachytherapy in the setting of newly diagnosed prostate cancer and those who have had recurrence after prior radiation therapy (radiorecurrence). Additionally, Dr. Solanki is also an leader in the treatment of bladder cancers, including the combination of immunotherapy with chemoradiation therapy for bladder preservation. Dr. Solanki a passionate clinical trialist. He is the national co-chair of the ECOG/NRG 8185 “INSPIRE” phase II trial comparing chemoradiotherapy with and without immunotherapy in node-positive bladder cancer. He is the PI of the multi-center FSHARP phase I/II trial of salvage high dose rate brachytherapy in patients with radiorecurrent prostate cancer. He serves as the PI of the Veterans Affairs seamless phase II/III randomized trial of STAndard systemic theRapy with or without PET-directed local therapy for OligoRecurrenT prostate cancer (VA STARPORT). This trial is comparing systemic therapy with or without metastasis-directed therapy for patients with recurrent prostate cancer after prostatectomy or radiation leveraging modern advanced PSMA PET imaging to identify oligometastatic disease. This study will definitively test the oligometastasis hypothesis in recurrent prostate cancer and is currently accruing at 16 VA medical centers across the United States. Dr. Solanki also conducts research identifying innovative methods to use modern information technologies to improve patient safety and quality in radiation oncology.
